Hawthorn

Hawthorn flavonoids and procyanidins have mild antiplatelet and anticoagulant properties. Combined with warfarin anticoagulation, there is additive bleeding risk. Additionally, hawthorn quercetin may weakly inhibit CYP2C9, potentially reducing S-warfarin clearance and elevating INR values.

Monitor INR when initiating or stopping hawthorn in patients on warfarin. Advise patients to report unusual bruising or prolonged bleeding. Discontinue hawthorn at least 2 weeks before elective surgery. Emphasize the need to disclose herbal supplement use at anticoagulation clinic appointments.

Hawthorn inhibits phosphodiesterase activity (similar mechanism to PDE5 inhibitors), causing vasodilation and blood pressure reduction. Combined with PDE5 inhibitors (which also cause vasodilation), there is additive hypotensive effect. The combination may produce sudden severe blood pressure drops, particularly in patients with cardiovascular disease.

Advise patients on PDE5 inhibitors to discuss hawthorn use with their clinician. Warn about dizziness, lightheadedness, and risk of syncope with this combination. Patients using PDE5 inhibitors for pulmonary arterial hypertension are at particularly elevated risk.

Hawthorn flavonoids and oligomeric procyanidins have positive inotropic and negative chronotropic properties, similar in mechanism to cardiac glycosides. Both hawthorn and digoxin bind to Na+/K+ ATPase and increase intracellular calcium. In vitro studies show additive calcium-mobilizing effects, and hawthorn alkaloids structurally resemble digoxin causing false-positive immunoassay interference. Concurrent use may potentiate digoxin effects and increase toxicity risk.

Avoid concurrent use; this combination has been declared a contraindication by PubMed pharmacology studies. If combined use is identified, monitor digoxin serum levels using the Tina-Quant assay (not Digoxin III immunoassay, which hawthorn interferes with), and monitor ECG. Adjust digoxin dose downward cautiously.

Hawthorn produces vasodilation through phosphodiesterase inhibition (increasing cAMP), endothelium-dependent mechanisms, and direct vasodilatory flavonoid effects. These blood pressure-lowering effects are additive with prescribed antihypertensives, potentially causing symptomatic hypotension, dizziness, and falls.

Monitor blood pressure when initiating hawthorn in patients on antihypertensives. Warn patients about orthostatic hypotension, especially when rising from sitting or lying positions. Dose adjustment of antihypertensive medications may be required. Hawthorn may be used cautiously as complementary therapy but requires clinician supervision.

Hawthorn produces significant coronary and peripheral vasodilation via flavonoid-mediated mechanisms. Combined with nitrate vasodilators, there is additive vasodilation producing excessive hypotension. Severe symptomatic hypotension with accompanying risk of syncope and myocardial ischemia from precipitous blood pressure drop is a documented concern.

Avoid hawthorn in patients prescribed nitrates for angina or heart failure. If patients insist on combined use, start with the lowest hawthorn dose, monitor blood pressure closely, and advise caution with position changes. Advise patients to sit down if they experience dizziness or lightheadedness.

Hawthorn (Crataegus) exerts negative chronotropic and mild hypotensive effects through inhibition of phosphodiesterase, increased nitric oxide production, and positive inotropic flavonoid activity. Beta-blockers reduce heart rate and blood pressure via beta-1 receptor antagonism. Combined use may produce additive bradycardia and hypotension beyond the effect of either agent alone.

Monitor blood pressure and heart rate when combining hawthorn with beta-blockers, particularly in patients already prone to bradycardia. Hawthorn may have synergistic benefit in heart failure (additive positive inotropy), but clinical supervision is required. Patients should not self-initiate hawthorn without informing their cardiologist.

Hawthorn oligomeric procyanidins and flavonoids promote coronary vasodilation and reduce systemic vascular resistance via mechanisms partially overlapping with calcium channel blockers (CCBs). Verapamil and diltiazem also carry negative chronotropic effects. Additive vasodilation, hypotension, and potential bradycardia may occur with concurrent use.

Monitor blood pressure and heart rate when hawthorn is used alongside CCBs. Combination with non-dihydropyridine CCBs (diltiazem, verapamil) carries greater risk for bradycardia. Caution in elderly patients and those with pre-existing hypotension. Document hawthorn use in the cardiology chart and adjust antihypertensive doses if needed.

Hawthorn flavonoids and procyanidins affect cardiac ion channel activity, with in vitro data suggesting potential QTc prolongation at higher doses. Co-administration with established QT-prolonging medications creates additive risk for dangerous arrhythmias including torsades de pointes and ventricular fibrillation.

Avoid combining hawthorn with drugs known to prolong the QT interval (vandetanib, azithromycin, sotalol, haloperidol, fluoroquinolones). Obtain baseline ECG before initiating hawthorn in patients on QT-prolonging drugs. If combination is unavoidable, implement more frequent ECG monitoring and electrolyte surveillance.

Hawthorn extracts exhibit class III antiarrhythmic-like cardiac electrophysiological effects via phosphodiesterase inhibition and prolongation of action potential duration. Combining with antiarrhythmic drugs may produce additive effects on cardiac conduction, increasing both antiarrhythmic benefit and risk of proarrhythmia or excessive QT prolongation.

Monitor cardiac rhythm (ECG) when hawthorn is combined with antiarrhythmic medications. Patients on amiodarone or quinidine are particularly at risk for cumulative cardiac effects. Advise patients with arrhythmia conditions to consult their cardiologist before initiating hawthorn. Avoid self-medication in this context.

Hawthorn contains mild CNS-sedative constituents including flavonoid glycosides with affinity for neuronal GABA receptor systems. Combining with sedating antihistamines or barbiturates may enhance CNS depression beyond the effect of either agent, leading to excess drowsiness, cognitive impairment, and psychomotor slowing.

Advise patients to exercise caution when combining hawthorn supplements with CNS depressants including sedating antihistamines (diphenhydramine, doxylamine) or barbiturates. Avoid driving or operating machinery if significant drowsiness occurs. The interaction risk is generally low at standard hawthorn doses.